T2 Biosystems Inc. (TTOO)

6.57
0.26 3.80
NASDAQ : Health Technology
Prev Close 6.83
Open 6.85
Day Low/High 6.50 / 6.85
52 Wk Low/High 2.50 / 7.54
Volume 149.04K
Avg Volume 290.50K
Exchange NASDAQ
Shares Outstanding 36.02M
Market Cap 250.34M
EPS -1.90
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Multiple New Studies Demonstrate T2 Biosystems' Diagnostics Improve Detection Of Sepsis Causing Pathogens Over Blood Culture-based Diagnostics

Multiple New Studies Demonstrate T2 Biosystems' Diagnostics Improve Detection Of Sepsis Causing Pathogens Over Blood Culture-based Diagnostics

U.S. and EU studies demonstrate that T2Dx diagnostics enable getting patients on the right therapy faster, improving outcomes, enhancing stewardship, and reducing the cost of care

T2 Biosystems Reports Fourth Quarter And Full-Year 2017 Financial Results And Business Update

T2 Biosystems Reports Fourth Quarter And Full-Year 2017 Financial Results And Business Update

Quarterly Product Revenue Up 125% Year-Over-Year and 76% Over the Prior Quarter

T2 Biosystems Awarded Up To $2 Million By CARB-X To Support Development Of New Tests On The T2Dx Instrument For Drug-Resistant Bacteria

T2 Biosystems Awarded Up To $2 Million By CARB-X To Support Development Of New Tests On The T2Dx Instrument For Drug-Resistant Bacteria

T2 Biosystems Awarded Up To $2 Million by CARB-X to Support Development of New Tests on the T2Dx Instrument for Drug-Resistant Bacteria

TTOO Crosses Above Average Analyst Target

TTOO Crosses Above Average Analyst Target

In recent trading, shares of T2 Biosystems Inc have crossed above the average analyst 12-month target price of $5.25, changing hands for $6.36/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.

3 Biotech Stocks I Love for March (Celgene Is One of Them)

3 Biotech Stocks I Love for March (Celgene Is One of Them)

These biotech names are all great buys on dips. Notably Celgene, which is fresh off a terrible trading session.

3 Promising Biotech Stocks to Buy on Dips

3 Promising Biotech Stocks to Buy on Dips

From ANI Pharmaceuticals to T2 Biosystems, these names look good.

Three Biotech Opportunities

Three Biotech Opportunities

Celgene, ANI and T2 are seeing attractive entry points.

Two New Studies Demonstrate T2Candida's Advantages Over Current Diagnostic Testing

Two New Studies Demonstrate T2Candida's Advantages Over Current Diagnostic Testing

Studies demonstrate T2Candida identifies infections missed by blood culture and the opportunity for faster targeted therapy

TTOO Crosses Above Average Analyst Target

TTOO Crosses Above Average Analyst Target

In recent trading, shares of T2 Biosystems Inc have crossed above the average analyst 12-month target price of $5.25, changing hands for $5.56/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.

Could These 2 Biotech 'Busted IPOs' Be the Next Ignyta?

Could These 2 Biotech 'Busted IPOs' Be the Next Ignyta?

After Roche's acquisition of Ignyta, I have high hopes for these other two names in 2018.

2 Biotech 'Busted IPOs' to Watch in 2018

2 Biotech 'Busted IPOs' to Watch in 2018

Are these names the next 'Ignytas'?

T2 Biosystems Announces New T2Bacteria RUO Panel Data Presented At AMP 2017

T2 Biosystems Announces New T2Bacteria RUO Panel Data Presented At AMP 2017

Results Show Detection of Clinically Important Infections Missed by Blood Culture

Clinicians Discuss Positive Impact Of T2MR Platform On Sepsis Care At IDWeek 2017

Clinicians Discuss Positive Impact Of T2MR Platform On Sepsis Care At IDWeek 2017

Clinicians present clinical and economic value of the T2Sepsis Solution and discuss potential of T2Bacteria Panel

T2 Biosystems Reaches Analyst Target Price

T2 Biosystems Reaches Analyst Target Price

In recent trading, shares of T2 Biosystems Inc have crossed above the average analyst 12-month target price of $4.33, changing hands for $4.36/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.

Study Published In Journal Of Antimicrobial Stewardship Shows Patients Diagnosed With T2Candida Panel Treated More Than Eight Times Faster

Study Published In Journal Of Antimicrobial Stewardship Shows Patients Diagnosed With T2Candida Panel Treated More Than Eight Times Faster

T2MR platform shown to lead to appropriate therapy in 5 hours compared to 44 hours based on blood culture

TheStreet Quant Rating: D- (Sell)